SCHEMBL13352014

SCHEMBL13352014

CCOc1cc(/C=C/C(=O)Nc2ccccc2C(=O)O)ccc1OC

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.83
KMT2A Q03164 6/20 0.83
ALDH1A1 P00352 6/20 0.83
HPGD P15428 5/20 0.83
NPC1 O15118 4/20 0.83
RAB9A P51151 4/20 0.83
KDM4E B2RXH2 4/20 0.83
SMN1; SMN2 Q16637 3/20 0.83
TP53 P04637 2/20 0.83
CYP3A4 P08684 2/20 0.83
HIF1A Q16665 2/20 0.83
PKM P14618 2/20 0.83
NPSR1 Q6W5P4 2/20 0.83
CYP1A2 P05177 1/20 0.83
CYP2C9 P11712 1/20 0.83
CYP2C19 P33261 1/20 0.83
HSD17B10 Q99714 1/20 0.83
ABCC4 O15439 1/20 0.83
HPGDS O60760 1/20 0.83
ABCB11 O95342 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13352266 0.96 MEN1 (0.83) MEN1KMT2AALDH1A1HPGDNPC1
SCHEMBL2777954 0.95 TRPA1 (0.84) MEN1KMT2AALDH1A1HPGDNPC1
SCHEMBL2777952 0.95 TRPA1 (0.84) MEN1KMT2AALDH1A1HPGDNPC1
SCHEMBL13352107 0.92 MEN1 (0.80) MEN1KMT2AALDH1A1HPGDNPC1
SCHEMBL8639755 0.92 ALDH1A1 (0.69) MEN1KMT2AALDH1A1HPGDNPC1
SCHEMBL8639760 0.92 ALDH1A1 (0.69) MEN1KMT2AALDH1A1HPGDNPC1
Tranilast SCHEMBL29875 0.91 MEN1 (1.00) MEN1KMT2AALDH1A1HPGDNPC1
Tranilast SCHEMBL8696829 0.91 MEN1 (1.00) MEN1KMT2AALDH1A1HPGDNPC1
Tranilast SCHEMBL10978582 0.91 MEN1 (1.00) MEN1KMT2AALDH1A1HPGDNPC1
Tranilast SCHEMBL29876 0.91 MEN1 (1.00) MEN1KMT2AALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180117050-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION OCCURX PTY LTD (AU) 2018-05-03 US disclosed
US-20100130497-A1 Therapeutic Compounds FIBROTECH THERAPEUTICS PTY LTD (AU) 2010-05-27 US disclosed
WO-2008003141-A1 THERAPEUTIC COMPOUNDS FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130497-A1 Therapeutic Compounds NFATC1, NAT1, AADAC MEN1 2640/4885KMT2A 1798/4885ALDH1A1 199/4885
US-20180117050-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION VCAM1, PTGIS, NFKBIA MEN1 3939/4885KMT2A 2447/4885ALDH1A1 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.